


**IN THE CLAIMS:**

Please cancel claims 7 to 10 without prejudice to Applicants' right to pursue the canceled subject matter in a later filed divisional or continuation application.

Claims 2, 3, and 17-20 were canceled in Applicants' April 29, 2003 Amendment, and claim 4 was canceled in Applicants' December 11, 2003 Amendment.

Please amend claim 1 pursuant to 37 C.F.R. §1.121, as follows:

1. (Currently Amended) A compound of the formula 1




or a pharmaceutically acceptable salt, ~~solvate~~ or prodrug thereof, wherein:

m is an integer from 0 to 3;

p is an integer from 0 to 4;

each R<sup>1</sup> and R<sup>2</sup> is independently selected from H and C<sub>1</sub>-C<sub>6</sub> alkyl;

R<sup>3</sup> is selected from



wherein the foregoing R<sup>3</sup> groups are optionally substituted by 1 to 3 R<sup>8</sup> groups;

R<sup>4</sup> is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$ ,  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_tR^9$ ,  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ , or  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ , or  $-(CR^{16}R^{17})_tR^9$ , wherein the

~~attachment point to R<sup>9</sup> is through a carbon atom of the R<sup>9</sup> group~~, each k is an integer from 1 to 3, ~~each t is an integer from 0 to 5~~, and each m is an integer from 0 to 3;

each R<sup>5</sup> is independently selected from halo, hydroxy, -NR<sup>1</sup>R<sup>2</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, trifluoromethyl, C<sub>1</sub>-C<sub>6</sub> alkoxy, trifluoromethoxy, -NR<sup>6</sup>C(O)R<sup>1</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>C(O)NR<sup>7</sup>R<sup>1</sup>, and -NR<sup>6</sup>C(O)OR<sup>7</sup>;

each R<sup>6</sup>, R<sup>6a</sup> and R<sup>7</sup> is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, the alkyl, aryl and heterocyclic moieties of the foregoing R<sup>6</sup> and R<sup>7</sup> groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, -NR<sup>1</sup>R<sup>2</sup>, trifluoromethyl, trifluoromethoxy, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, hydroxy, and C<sub>1</sub>-C<sub>6</sub> alkoxy;

or R<sup>6</sup> and R<sup>7</sup>, or R<sup>6a</sup> and R<sup>7</sup>, when attached to the same nitrogen atom, can be taken together to form a 4 to 10 membered heterocyclic ring which may include 1 to 3 additional hetero moieties, in addition to the nitrogen to which said R<sup>6</sup>, R<sup>6a</sup>, and R<sup>7</sup> are attached, selected from N, N(R<sup>1</sup>), O, and S, provided two O atoms, two S atoms or an O and S atom are not attached directly to each other;

each R<sup>8</sup> is independently selected from oxo (=O), halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C<sub>1</sub>-C<sub>6</sub> alkoxy, C<sub>1</sub>-C<sub>10</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, -C(O)R<sup>6</sup>, -C(O)OR<sup>6</sup>, -OC(O)R<sup>6</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -NR<sup>6</sup>SO<sub>2</sub>NR<sup>7</sup>R<sup>1</sup>, -NR<sup>6</sup>C(O)NR<sup>1</sup>R<sup>7</sup>, -NR<sup>6</sup>C(O)OR<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>OR<sup>7</sup>, -SO<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -S(O)<sub>j</sub>(C<sub>1</sub>-C<sub>6</sub> alkyl) wherein j is an integer from 0 to 2, -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), -(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>C(O)(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>C(O)(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>O(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>O(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>(4 to 10 membered heterocyclic), -(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>S(O)<sub>j</sub>(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CR<sup>1</sup>R<sup>2</sup>)<sub>q</sub>S(O)<sub>j</sub>(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein j is 0, 1 or 2, q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R<sup>8</sup> groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R<sup>8</sup> groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, -OR<sup>6</sup>, -C(O)R<sup>6</sup>, -C(O)OR<sup>6</sup>, -OC(O)R<sup>6</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -C(O)NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>OR<sup>7</sup>, C<sub>1</sub>-C<sub>6</sub> alkyl, C<sub>2</sub>-C<sub>6</sub> alkenyl, C<sub>2</sub>-C<sub>6</sub> alkynyl, -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), and -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5;

~~R<sup>9</sup> is a non-aromatic mono-cyclic ring, a fused or bridged bicyclic ring, or a spirocyclic ring, wherein said ring contains from 3 to 12 carbon atoms in which from 0 to 3 carbon atoms are optionally replaced with a hetero moiety independently selected from N, O, S(O)<sub>j</sub>, wherein j is an integer from 0 to 2, and -NR<sup>1</sup>, provided that two O atoms, two S(O)<sub>j</sub> moieties, an O atom and a S(O)<sub>j</sub> moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other within said ring, and wherein the carbon atoms of said ring are optionally substituted with 1 or 2 R<sup>8</sup> groups;~~

each R<sup>11</sup> is independently selected from the substituents provided in the definition of R<sup>8</sup>, except R<sup>11</sup> is not oxo(=O);

R<sup>12</sup> is R<sup>6</sup>, -OR<sup>6</sup>, -OC(O)R<sup>6</sup>, -OC(O)NR<sup>6</sup>R<sup>7</sup>, -OCO<sub>2</sub>R<sup>6</sup>, -S(O)<sub>j</sub>R<sup>6</sup>, -S(O)<sub>j</sub>NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>, -NR<sup>6</sup>C(O)NR<sup>6a</sup>R<sup>7</sup>, -NR<sup>6</sup>SO<sub>2</sub>NR<sup>6a</sup>R<sup>7</sup>, -NR<sup>6</sup>CO<sub>2</sub>R<sup>7</sup>, CN, -C(O)R<sup>6</sup>, or halo, wherein j is an integer from 0 to 2;

R<sup>13</sup> is -NR<sup>1</sup>R<sup>14</sup> or -OR<sup>14</sup>;

R<sup>14</sup> is H, R<sup>15</sup>, -C(O)R<sup>15</sup>, -SO<sub>2</sub>R<sup>15</sup>, -C(O)NR<sup>15</sup>R<sup>7</sup>, -SO<sub>2</sub>NR<sup>15</sup>R<sup>7</sup>, or -CO<sub>2</sub>R<sup>15</sup>;

R<sup>15</sup> is R<sup>18</sup>, -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(C<sub>6</sub>-C<sub>10</sub> aryl), -(CR<sup>1</sup>R<sup>2</sup>)<sub>t</sub>(4 to 10 membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the aryl and heterocyclic moieties of the foregoing R<sup>15</sup> groups are optionally substituted with 1 to 3 R<sup>8</sup> substituents;

each R<sup>16</sup> and R<sup>17</sup> is independently selected from H, C<sub>1</sub>-C<sub>6</sub> alkyl, and -CH<sub>2</sub>OH, or R<sup>16</sup> and R<sup>17</sup> are taken together as -CH<sub>2</sub>CH<sub>2</sub>- or -CH<sub>2</sub>CH<sub>2</sub>CH<sub>2</sub>-;

R<sup>18</sup> is C<sub>1</sub>-C<sub>6</sub> alkyl wherein each carbon not bound to a N or O atom, or to S(O)<sub>j</sub>, wherein j is an integer from 0 to 2, is optionally substituted with R<sup>12</sup>;

and wherein any of the above-mentioned substituents comprising a CH<sub>3</sub> (methyl), CH<sub>2</sub> (methylene), or CH (methine) group, which is not attached to a halogeno, SO or SO<sub>2</sub> group or to a N, O or S atom, is optionally substituted with a group selected from hydroxy, halo, C<sub>1</sub>-C<sub>4</sub> alkyl, C<sub>1</sub>-C<sub>4</sub> alkoxy and -NR<sup>1</sup>R<sup>2</sup>.


2. Canceled

3. Canceled

4. Canceled

5. (Original) A compound according to claim 1 wherein  $R^3$  is pyridin-3-yl optionally substituted by 1 to 3  $R^8$  groups.

6. (Previously Amended) A compound according to claim 1 wherein the following structural portion of the compound of formula 1



is selected from the group consisting of

3-Methyl-4-(pyridin-2-yloxy)-phenylamino  
3-Chloro-4-(pyridin-2-yloxy)-phenylamino  
3-Methoxy-4-(pyridin-2-yloxy)-phenylamino  
4-(pyridin-2-yloxy)-phenylamino  
2-Methyl-4-(pyridin-2-yloxy)-phenylamino  
2-Methoxy-4-(pyridin-2-yloxy)-phenylamine  
3-Chloro-4-(6-methyl-pyridin-2-yloxy)-phenylamino  
3-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino  
3-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino  
2-Methoxy-4-(6-methyl-pyridin-2-yloxy)-phenylamino  
2-Methyl-4-(6-methyl-pyridin-2-yloxy)-phenylamino  
4-(6-methyl-pyridin-2-yloxy)-phenylamino  
3-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino  
3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino  
3-Chloro-4-(2-methyl-pyridin-3-yloxy)-phenylamino  
2-Methoxy-4-(2-methyl-pyridin-3-yloxy)-phenylamino  
2-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino  
4-(2-methyl-pyridin-3-yloxy)-phenylamino  
3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino  
3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino  
3-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino  
2-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino

2-Methoxy-4-(6-methyl-pyridin-3-yloxy)-phenylamino  
4-(6-methyl-pyridin-3-yloxy)-phenylamino  
3-Methyl-4-(pyridin-3-yloxy)-phenylamino  
3-Chloro-4-(pyridin-3-yloxy)-phenylamino  
3-Methoxy-4-(pyridin-3-yloxy)-phenylamino  
2-Methyl-4-(pyridin-3-yloxy)-phenylamino  
2-Methoxy-4-(pyridin-3-yloxy)-phenylamino  
4-(pyridin-3-yloxy)-phenylamino  
3-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Chloro-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
2-Methyl-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
2-Methoxy-4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
4-(2-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Chloro-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
2-Methyl-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
2-Methoxy-4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
4-(4-methyl-pyrimidin-5-yloxy)-phenylamino  
3-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
3-Chloro-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
3-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
2-Methyl-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
2-Methoxy-4-(2-methyl-pyridin-4-yloxy)-phenylamino  
4-(2-methyl-pyridin-4-yloxy)-phenylamino  
3-Methyl-4-(pyridin-4-yloxy)-phenylamino  
3-Chloro-4-(pyridin-4-yloxy)-phenylamino  
3-Methoxy-4-(pyridin-4-yloxy)-phenylamino  
2-Methyl-4-(pyridin-4-yloxy)-phenylamino  
2-Methoxy-4-(pyridin-4-yloxy)-phenylamino  
4-(pyridin-4-yloxy)-phenylamino  
3-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino

3-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
3-Chloro-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
2-Methyl-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
2-Methoxy-4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
4-(2-methyl-pyrimidin-4-yloxy)-phenylamino  
3-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
3-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
3-Chloro-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
2-Methyl-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
2-Methoxy-4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
4-(6-methyl-pyrimidin-4-yloxy)-phenylamino  
~~3-Methyl-4-(pyrazin-2-yloxy)-phenylamino~~  
~~3-Methoxy-4-(pyrazin-2-yloxy)-phenylamino~~  
~~3-Chloro-4-(pyrazin-2-yloxy)-phenylamino~~  
~~2-Methyl-4-(pyrazin-2-yloxy)-phenylamino~~  
~~2-Methoxy-4-(pyrazin-2-yloxy)-phenylamino~~  
~~4-(pyrazin-2-yloxy)-phenylamino~~  
~~3-Chloro-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~2-Methoxy-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~2-Methyl-4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~4-(3-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Chloro-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~2-Methoxy-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~2-Methyl-4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~4-(5-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Chloro-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~3-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~2-Methoxy-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~

~~2-Methyl-4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~  
~~4-(6-methyl-pyrazin-2-yloxy)-phenylamino~~  
3-Methyl-4-(pyridazin-3-yloxy)-phenylamino  
3-Chloro-4-(pyridazin-3-yloxy)-phenylamino  
3-Methoxy-4-(pyridazin-3-yloxy)-phenylamino  
2-Methyl-4-(pyridazin-3-yloxy)-phenylamino  
2-Methoxy-4-(pyridazin-3-yloxy)-phenylamino  
4-(pyridazin-3-yloxy)-phenylamino  
3-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
3-Chloro-4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
3-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
2-Methyl-4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
2-Methoxy-4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
4-(6-methyl-pyridazin-3-yloxy)-phenylamino  
3-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
3-Chloro-4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
3-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
2-Methyl-4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
2-Methoxy-4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
4-(6-methyl-pyridazin-4-yloxy)-phenylamino  
3-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
3-Chloro-4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
3-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
2-Methyl-4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
2-Methoxy-4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
4-(3-methyl-pyridazin-4-yloxy)-phenylamino  
3-Methyl-4-(pyridazin-4-yloxy)-phenylamino  
3-Chloro-4-(pyridazin-4-yloxy)-phenylamino  
3-Methoxy-4-(pyridazin-4-yloxy)-phenylamino  
2-Methyl-4-(pyridazin-4-yloxy)-phenylamino  
2-Methoxy-4-(pyridazin-4-yloxy)-phenylamino  
4-(pyridazin-4-yloxy)-phenylamino  
3-Chloro-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino

3-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino  
3-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino  
2-Methoxy-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino  
2-Methyl-4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino, and  
4-(1-methyl-1H-pyrazol-4-yloxy)-phenylamino.

7. Canceled

8. Canceled

9. Canceled

10. Canceled

11. (Original) A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ , wherein k is an integer from 1 to 3 and m is an integer from 0 to 3.

12. (Original) A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$ , wherein k is an integer from 1 to 3 and m is an integer from 0 to 3, wherein  $R^{13}$  is  $-NR^1R^{14}$ , wherein  $R^{14}$  is selected from  $-C(O)R^{15}$ ,  $-SO_2R^{15}$ , and  $-C(O)NR^{15}R^7$ .

13. (Original) A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein k is an integer from 1 to 3 and m is an integer from 0 to 3.

14. (Original) A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein k is an integer from 1 to 3 and m is an integer from 0 to 3, wherein  $R^{13}$  is  $-NR^1R^{14}$ , wherein  $R^{14}$  is selected from  $-C(O)R^{15}$ ,  $-SO_2R^{15}$ , and  $-C(O)NR^{15}R^7$ .

15. (Original) A compound according to claim 1 wherein  $R^4$  is  $-(CR^{16}R^{17})_m-C\equiv C-(CR^{16}R^{17})_kR^{13}$  or  $-(CR^{16}R^{17})_m-C=C-(CR^{16}R^{17})_kR^{13}$ , wherein k is an integer from 1 to 3 and m is an integer from 0 to 3,  $R^{13}$  is  $-NR^1R^{14}$  or  $-OR^{14}$ ,  $R^{14}$  is  $R^{15}$ ,  $R^{15}$  is  $R^{18}$ , and  $R^{18}$  is  $C_1-C_6$  alkyl



optionally substituted by -OR<sup>6</sup>, -S(O)<sub>j</sub>R<sup>6</sup>, -NR<sup>6</sup>R<sup>7</sup>, -NR<sup>6</sup>C(O)R<sup>7</sup>, -NR<sup>6</sup>SO<sub>2</sub>R<sup>7</sup>, -NR<sup>6</sup>CO<sub>2</sub>R<sup>7</sup>, CN, -C(O)R<sup>6</sup>, or halo.

16. (Original) A compound according to claim 1 selected from the group consisting of:

(±)-[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

(±)-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-3-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(2-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide

[3-Methyl-4-(2-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine

[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

2-Fluoro-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

*E*-2-Methoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

[3-Methyl-4-(pyridin-3-yloxy)-phenyl]-(6-piperidin-4-ylethynyl-quinazolin-4-yl)-amine;

2-Methoxy-N-(1-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-ylethynyl}-cyclopropyl)-acetamide;

*E*-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-2-methoxy-acetamide;

N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

*E*-N-(3-{4-[3-Chloro-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

*E*-2-Ethoxy-N-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-acetamide;

1-Ethyl-3-(3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-urea;

Piperazine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

(±)-2-Hydroxymethyl-pyrrolidine-1-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

2-Dimethylamino-N-(3-{4-[3-methyl-4-(pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-acetamide;

*E*-N-(3-{4-[3-Methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-allyl)-methanesulfonamide;

Isoxazole-5-carboxylic acid (3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-amide;

1-(1,1-Dimethyl-3-{4-[3-methyl-4-(6-methyl-pyridin-3-yloxy)-phenylamino]-quinazolin-6-yl}-prop-2-ynyl)-3-ethyl-urea;

and the pharmaceutically acceptable salts, prodrugs and solvates of the foregoing compounds.

17. Canceled

18. Canceled

19. Canceled

20. Canceled

21. (Original) A pharmaceutical composition for the treatment of abnormal cell growth in a mammal comprising an amount of a compound of claim 1 that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier.